Skip to main content
BIIB
NASDAQ Life Sciences

Biogen Pre-Announces Significant Q2 & Q3 R&D Charges, Impacting EPS by up to $2.90/Share

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$209.74
Mkt Cap
$30.965B
52W Low
$121.05
52W High
$219.72
52W Position info
73% above low
Off High info
4.5% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

BIIB sits 73% above its 52-week low of $121.05.

Summary

Biogen expects to incur significant R&D and milestone expenses in Q2 and Q3 2026, leading to an estimated combined EPS reduction of up to $2.90 per share.


Key Events · Earnings and Guidance · BIIB

  • Q2 2026 EPS Impact

    Biogen anticipates approximately $164 million in pre-tax acquired in-process R&D, upfront, and milestone expenses for Q2 2026, impacting EPS by about $0.95 per share.

  • Q3 2026 EPS Impact

    The company expects Q3 2026 to include $290 million to $320 million in similar expenses, leading to an estimated EPS reduction of $1.75 to $1.95 per share.

  • Preliminary Estimates

    These figures are preliminary and unaudited, subject to final financial statement closing procedures.


Analysis · BIIB · Life Sciences

Biogen is pre-announcing substantial acquired in-process R&D, upfront, and milestone expenses for Q2 and Q3 2026. These charges, totaling approximately $454 million to $484 million, will significantly reduce reported GAAP and non-GAAP earnings per share for both quarters. This update indicates higher-than-anticipated costs related to collaborations and acquisitions, which could lead to further downward revisions of full-year profit forecasts and negatively impact investor sentiment, especially as the stock trades near its 52-week high.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BIIB was trading at $209.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31B. The 52-week trading range was $121.05 to $219.72. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BIIB - Latest Insights

BIIB
Nov 18, 2026, 11:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $249.28
Real-time Price: $247.13 info
Change: -$2.15 (-0.86%) info
Market Cap: $36.531B info
BIIB
Nov 17, 2026, 4:45 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $253.00
Real-time Price: $247.13 info
Change: -$5.87 (-2%) info
Market Cap: $36.531B info
BIIB
Nov 09, 2026, 1:02 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $248.35
Real-time Price: $247.13 info
Change: -$1.22 (-0.49%) info
Market Cap: $36.531B info
BIIB
Oct 28, 2026, 6:23 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $247.13 info
Change: -$5.60 (-2%) info
Market Cap: $36.531B info
BIIB
Oct 28, 2026, 6:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $247.13 info
Change: -$5.60 (-2%) info
Market Cap: $36.531B info